• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing Lu-PSMA Therapy.

作者信息

Ahmadzadehfar Hojjat, Essler Markus

机构信息

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

出版信息

J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.

DOI:10.2967/jnumed.118.209270
PMID:29653975
Abstract
摘要

相似文献

1
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing Lu-PSMA Therapy.接受镥-PSMA治疗的去势抵抗性转移性前列腺癌患者反应和总生存期的预测因素
J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.
2
Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.三线治疗和 Lu-PSMA 放射性配体疗法治疗转移性去势抵抗性前列腺癌：系统评价。
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16.
3
The Ga/Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV values and absorbed dose estimates.镓/镥治疗诊断一体化概念在去势抵抗性前列腺癌的前列腺特异性膜抗原靶向治疗中的应用：标准化摄取值与吸收剂量估计值的相关性
Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12.
4
Real-world Outcomes and Predictive Biomarkers for Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study.镥标记前列腺特异性膜抗原配体治疗转移性去势抵抗性前列腺癌的真实世界结局和预测生物标志物：欧洲泌尿外科学会青年学术泌尿外科医生前列腺癌工作组多机构观察性研究
Eur Urol Oncol. 2024 Jun;7(3):421-429. doi: 10.1016/j.euo.2023.07.018. Epub 2023 Aug 19.
5
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.放射性配体疗法联合（177）Lu 标记的前列腺特异性膜抗原配体在转移性去势抵抗性前列腺癌患者的成像和治疗中的应用。
J Urol. 2016 Aug;196(2):382-91. doi: 10.1016/j.juro.2016.02.2969. Epub 2016 Mar 8.
6
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.前列腺特异性膜抗原的影像学表现与转移性去势抵抗性前列腺癌对 PSMA 靶向β发射放射性核素治疗的反应
Prostate. 2021 Apr;81(5):279-285. doi: 10.1002/pros.24104. Epub 2021 Jan 19.
7
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.225Ac-PSMA-617用于转移性去势抵抗性前列腺癌的PSMA靶向α放射治疗。
J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.
8
Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements.转移性去势抵抗性前列腺癌的 Lu-PSMA-RLT：局限性与改进。
Ann Nucl Med. 2021 Aug;35(8):861-870. doi: 10.1007/s12149-021-01649-w. Epub 2021 Jun 27.
9
Early Prostate-Specific Antigen Changes and Clinical Outcome After Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer.Lu-PSMA 放射性核素治疗转移性去势抵抗性前列腺癌患者后的早期前列腺特异性抗原变化和临床结局。
J Nucl Med. 2020 Oct;61(10):1476-1483. doi: 10.2967/jnumed.119.240242. Epub 2020 Feb 28.
10
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.放射性核素标记前列腺特异性膜抗原配体治疗去势抵抗性前列腺癌患者内脏转移对预测疗效和生存结局的价值：系统评价和荟萃分析。
Clin Nucl Med. 2020 Dec;45(12):935-942. doi: 10.1097/RLU.0000000000003307.

引用本文的文献

1
Dealing with radiation risks in systemic cancer treatment: Perspectives of practitioners and patients in French hospitals.应对系统性癌症治疗中的辐射风险：法国医院从业者与患者的观点
PLoS One. 2025 Mar 6;20(3):e0316998. doi: 10.1371/journal.pone.0316998. eCollection 2025.
2
PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?靶向前列腺特异性膜抗原在转移性去势抵抗性前列腺癌中的应用：我们目前的状况与未来的发展方向？
Ther Adv Med Oncol. 2021 Oct 26;13:17588359211053898. doi: 10.1177/17588359211053898. eCollection 2021.
3
PSMA Theranostics: Science and Practice.
前列腺特异性膜抗原诊疗学：科学与实践
Cancers (Basel). 2021 Aug 2;13(15):3904. doi: 10.3390/cancers13153904.
4
Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review.预测转移性去势抵抗性前列腺癌患者接受[Lu]Lu-PSMA 放射性配体治疗后生化缓解和生存获益的因素：综述。
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4028-4041. doi: 10.1007/s00259-021-05237-y. Epub 2021 Mar 6.
5
The Ga/Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.镓/镥治疗诊断一体化概念在转移性去势抵抗性前列腺癌的前列腺特异性膜抗原靶向治疗中的应用：治疗后全身闪烁扫描在随访中的影响
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):695-712. doi: 10.1007/s00259-019-04583-2. Epub 2019 Nov 27.
6
Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.使用放射性标记的前列腺特异性膜抗原（PSMA）抑制剂对前列腺癌进行靶向α治疗：核医学领域的变革者。
Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018.